Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vanguard, CeNeS seek mass

Consolidation as a means to build critical mass is still very much in the cards in the U.K. biotech sector. Vanguard Medica Group plc and CeNeS Pharmaceuticals plc - two companies that started life with very different strategies - last week confirmed that they

Read the full 444 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers